W. Scott Melvin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
W. Scott Melvin has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Bradley J. Needleman
Center for Minimally Invasive Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio
8 shared publications - Dean J. Mikami
The Ohio State University Wexner Medical Center
6 shared publications E C Ellison
4 shared publicationsGuo-Du Wang
4 shared publications- Jackie Dale Wood
The Ohio State University College of Medicine
4 shared publications Xiyu Wang
4 shared publications
Latest Publications
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1761 Extra-Esophageal Symptoms in Patients Undergoing Magnetic Sphincter Augmentation for GERD: Clinical Outcomes At 3 Years
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1761 Extra-Esophageal Symptoms in Patients Undergoing Magnetic Sphincter Augmentation for GERD: Clinical Outcomes At 3 Years
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e14558
A dose-escalating and pharmacodynamic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and radiation in patients with locally advanced pancreas cancer.
E14558 Background: Pancreas cancer is a leading cause of cancer death in the US. Chemoradiation, a standard therapy for patients with locally advanced pancreas cancer (LAPCA), has resulted in modest improvement in outcome. Triapine, an inhibitor of the M2 subunit of ribonucleotide reductase, was shown to be a radiosensitizer in preclinical and early clinical studies. Methods: This is a dose escalation trial with three dose levels of triapine (24 mg/m2, 48 mg/m2, 72 mg/m2) administered concurrently with a total of 50.4 Gy of radiation in 28 fractions. Patients with LAPCA were given triapine intravenously over 2 hours, within 30 minutes of radiation, every Monday Wednesday and Friday, every other week for 5 ½ weeks. The primary endpoint was to determine the maximum tolerated dose (MTD) of triapine in combination with radiation. Secondary endpoints included response and radiographic correlates with dynamic contrast enhanced (DCE) MRI. Results: Eleven patients were treated. Three patients were non-evaluable (NE) for the primary endpoint due to disease progression prior to completion of therapy (2) or other (1). Four patients (1 NE) were enrolled at dose level 1, 3 patients at dose level 2, and 4 patients (2NE) at dose level 3 with the fourth patient still undergoing treatment. A fifth and last patient is scheduled to begin treatment at dose level 3, which is the highest planned dose level. No DLTs have been observed so far. The only related grade 3 toxicity was thrombocytopenia in 1 patient at dose level 2. Two of ten (20%) patients evaluable for response achieved a PR. One patient underwent successful surgical resection after therapy. mPFS is 4 months (95% CI 1-10) and mOS 7.5 months (95% CI 3-15.8). DCE MRI was shown to be a potential early predictor for response to therapy in LAPCA. Conclusions: The combination of triapine and radiation is safe and tolerable in patients with LAPCA with evidence of preliminary activity. DCE MRI is a potentially useful imaging tool to predict early response to therapy in patients with LAPCA and deserves further investigation. Final results including the recommended phase II dosing will be presented at the meeting.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e14558
A dose-escalating and pharmacodynamic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and radiation in patients with locally advanced pancreas cancer.
E14558 Background: Pancreas cancer is a leading cause of cancer death in the US. Chemoradiation, a standard therapy for patients with locally advanced pancreas cancer (LAPCA), has resulted in modest improvement in outcome. Triapine, an inhibitor of the M2 subunit of ribonucleotide reductase, was shown to be a radiosensitizer in preclinical and early clinical studies. Methods: This is a dose escalation trial with three dose levels of triapine (24 mg/m2, 48 mg/m2, 72 mg/m2) administered concurrently with a total of 50.4 Gy of radiation in 28 fractions. Patients with LAPCA were given triapine intravenously over 2 hours, within 30 minutes of radiation, every Monday Wednesday and Friday, every other week for 5 ½ weeks. The primary endpoint was to determine the maximum tolerated dose (MTD) of triapine in combination with radiation. Secondary endpoints included response and radiographic correlates with dynamic contrast enhanced (DCE) MRI. Results: Eleven patients were treated. Three patients were non-evaluable (NE) for the primary endpoint due to disease progression prior to completion of therapy (2) or other (1). Four patients (1 NE) were enrolled at dose level 1, 3 patients at dose level 2, and 4 patients (2NE) at dose level 3 with the fourth patient still undergoing treatment. A fifth and last patient is scheduled to begin treatment at dose level 3, which is the highest planned dose level. No DLTs have been observed so far. The only related grade 3 toxicity was thrombocytopenia in 1 patient at dose level 2. Two of ten (20%) patients evaluable for response achieved a PR. One patient underwent successful surgical resection after therapy. mPFS is 4 months (95% CI 1-10) and mOS 7.5 months (95% CI 3-15.8). DCE MRI was shown to be a potential early predictor for response to therapy in LAPCA. Conclusions: The combination of triapine and radiation is safe and tolerable in patients with LAPCA with evidence of preliminary activity. DCE MRI is a potentially useful imaging tool to predict early response to therapy in patients with LAPCA and deserves further investigation. Final results including the recommended phase II dosing will be presented at the meeting.
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Dopaminergic Control of Mucosal Secretion in Human Small Intestine
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Dopaminergic Control of Mucosal Secretion in Human Small Intestine
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
S1796 Stimulation of Intramural Spinal Afferents With Capsaicin Enhances Purinergic Inhibitory Neuromuscular Transmission in Human Jejunum
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
S1796 Stimulation of Intramural Spinal Afferents With Capsaicin Enhances Purinergic Inhibitory Neuromuscular Transmission in Human Jejunum
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
T2054 Platelet Activating Factor (PAF) Enhances Secretion and Motility in Human Small Intestine
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
T2054 Platelet Activating Factor (PAF) Enhances Secretion and Motility in Human Small Intestine
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
T2047 Mast Cell Activation by Corticotropin Releasing Factor (CRF) in Guinea Pig and Human Intestine
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
T2047 Mast Cell Activation by Corticotropin Releasing Factor (CRF) in Guinea Pig and Human Intestine
- 28 February 2009
- Published by Elsevier in Journal of Surgical Research
- Vol. 151 (2) , 304
QS474. Laparoscopic Distal Pancreatectomy With and Without Splenectomy: A Retrospective Review
- 28 February 2009
- Published by Elsevier in Journal of Surgical Research
- Vol. 151 (2) , 304
QS474. Laparoscopic Distal Pancreatectomy With and Without Splenectomy: A Retrospective Review
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-903-903
W1666 Endolumenal Fundoplication with EsophyX™: the Initial North American Experience
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-903-903
W1666 Endolumenal Fundoplication with EsophyX™: the Initial North American Experience
- 28 February 2006
- Published by Elsevier in Journal of Surgical Research
- Vol. 130 (2) , 304
Laparoscopic total pancreatectomy in domestic swine: A novel technique to provide a large animal model of insulin dependant diabetes
- 28 February 2006
- Published by Elsevier in Journal of Surgical Research
- Vol. 130 (2) , 304
Laparoscopic total pancreatectomy in domestic swine: A novel technique to provide a large animal model of insulin dependant diabetes